Extensive Pipeline of Clinical Programs and Drug Targets 
Lexicon’s robust drug discovery process has delivered more than 100 promising drug targets.  Our medicinal chemistry and biotherapeutic capabilities deliver new chemical entities, antibodies, and therapeutic proteins for our targets, which are associated with novel mechanisms of action.  We have created an extensive pipeline of clinical and preclinical programs across a broad range of therapeutic areas:  Cardiology, Gastroenterology, Immunology and Oncology, Metabolism, Neurology, and Ophthalmology. 

Multiple Long-term Alliances
We have established multiple long-term alliances with large pharmaceutical and biotechnology companies, many of which have been extended.  We also have an active alliance management group that focuses on delivering the promise inherent in our alliances. 

Commitment to Excellence
Lexicon brings a commitment to excellence, dedication, and extensive expertise to its alliances, and we continue to look for alliances that complement our internal capabilities and accelerate development and commercialization of our novel drug candidates.  This applies especially in therapeutic areas requiring significant development resources and commercialization infrastructure.  We are open to establishing relationships that satisfy the needs of both Lexicon and our partners as we translate our innovative pipeline into novel therapies for patients in need.  For further inquiries or interests in alliance opportunities with Lexicon, please contact us at This e-mail address is being protected from spambots, you need JavaScript enabled to view it .